Oncoinvent Hits 50% Phase 2 Enrollment For Radspherin In Treating Ovarian Cancer; Stock Up

Oncoinvent ASA announced 50% enrollment completion in its Phase 2 trial of Radspherin for peritoneal metastasis of ovarian cancer. The update signals steady clinical progress for the radiopharmaceutical program, but it does not include efficacy or safety results. The news is modestly positive for development momentum, though likely limited in immediate market impact.

Analysis

Oncoinvent ASA announced 50% enrollment completion in its Phase 2 trial of Radspherin for peritoneal metastasis of ovarian cancer. The update signals steady clinical progress for the radiopharmaceutical program, but it does not include efficacy or safety results. The news is modestly positive for development momentum, though likely limited in immediate market impact.